Recursion Pharmaceuticals, Inc. has filed a Form 8-K with the SEC on August 28, 2024, detailing its ongoing acquisition process of Exscientia plc. The acquisition, which was initially disclosed in a previous report on August 8, 2024, is subject to stockholder approval from both companies and will be executed through a Scheme of Arrangement under UK law. As part of the acquisition agreement, shareholders of Exscientia holding approximately 42% of its share capital have committed to vote in favor of the transaction through irrevocable undertakings. Additionally, Evotec SE, holding about 11% of Exscientia's share capital, has also entered into an irrevocable undertaking to support the acquisition. Collectively, these shareholders control approximately 53% of Exscientia's shares. The transaction is to be further detailed in a joint proxy statement to be filed with the SEC, which will outline the terms and benefits of the proposed acquisition. Recursion Pharmaceuticals advises investors and security holders to read the proxy statement and other relevant documents carefully once available, as they will contain important information about the transaction.

Recursion Pharmaceuticals, Inc. has filed a Form 8-K with the SEC on August 28, 2024, detailing its ongoing acquisition process of Exscientia plc. The acquisition, which was initially disclosed in a previous report on August 8, 2024, is subject to stockholder approval from both companies and will be executed through a Scheme of Arrangement under UK law. As part of the acquisition agreement, shareholders of Exscientia holding approximately 42% of its share capital have committed to vote in favor of the transaction through irrevocable undertakings. Additionally, Evotec SE, holding about 11% of Exscientia's share capital, has also entered into an irrevocable undertaking to support the acquisition. Collectively, these shareholders control approximately 53% of Exscientia's shares. The transaction is to be further detailed in a joint proxy statement to be filed with the SEC, which will outline the terms and benefits of the proposed acquisition. Recursion Pharmaceuticals advises investors and security holders to read the proxy statement and other relevant documents carefully once available, as they will contain important information about the transaction.